336 related articles for article (PubMed ID: 32164080)
1. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
Li H; Wang YM; Xu JY; Cao B
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):170-172. PubMed ID: 32164080
[TBL] [Abstract][Full Text] [Related]
2. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
Li H; Wang YM; Xu JY; Cao B
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(0):E002. PubMed ID: 32023685
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for COVID-19: The reality and challenges.
Jean SS; Lee PI; Hsueh PR
J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583
[TBL] [Abstract][Full Text] [Related]
5. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
[TBL] [Abstract][Full Text] [Related]
6. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.
Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S
Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.
Zeng YM; Xu XL; He XQ; Tang SQ; Li Y; Huang YQ; Harypursat V; Chen YK
Chin Med J (Engl); 2020 May; 133(9):1132-1134. PubMed ID: 32149772
[No Abstract] [Full Text] [Related]
8. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
Xu J; Shi PY; Li H; Zhou J
ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
[TBL] [Abstract][Full Text] [Related]
9. Clinical Analysis of 25 COVID-19 Infections in Children.
Bai K; Liu W; Liu C; Fu Y; Hu J; Qin Y; Zhang Q; Chen H; Xu F; Li C
Pediatr Infect Dis J; 2020 Jul; 39(7):e100-e103. PubMed ID: 32520888
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Momattin H; Al-Ali AY; Al-Tawfiq JA
Travel Med Infect Dis; 2019; 30():9-18. PubMed ID: 31252170
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.
Ford N; Vitoria M; Rangaraj A; Norris SL; Calmy A; Doherty M
J Int AIDS Soc; 2020 Apr; 23(4):e25489. PubMed ID: 32293807
[TBL] [Abstract][Full Text] [Related]
12. Potential treatment methods targeting 2019-nCoV infection.
Zheng L; Zhang L; Huang J; Nandakumar KS; Liu S; Cheng K
Eur J Med Chem; 2020 Nov; 205():112687. PubMed ID: 32771797
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients.
Li L; Wang X; Wang R; Hu Y; Jiang S; Lu X
Drug Des Devel Ther; 2020; 14():3001-3013. PubMed ID: 32801640
[TBL] [Abstract][Full Text] [Related]
14. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.
Khan Z; Karataş Y; Rahman H
Adv Ther; 2020 Jun; 37(6):2575-2579. PubMed ID: 32350686
[TBL] [Abstract][Full Text] [Related]
15. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Sheahan TP; Sims AC; Leist SR; Schäfer A; Won J; Brown AJ; Montgomery SA; Hogg A; Babusis D; Clarke MO; Spahn JE; Bauer L; Sellers S; Porter D; Feng JY; Cihlar T; Jordan R; Denison MR; Baric RS
Nat Commun; 2020 Jan; 11(1):222. PubMed ID: 31924756
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Drug Discovery Using Intensive Approaches.
Asai A; Konno M; Ozaki M; Otsuka C; Vecchione A; Arai T; Kitagawa T; Ofusa K; Yabumoto M; Hirotsu T; Taniguchi M; Eguchi H; Doki Y; Ishii H
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325767
[TBL] [Abstract][Full Text] [Related]
17. Potential specific therapies in COVID-19.
Gul MH; Htun ZM; Shaukat N; Imran M; Khan A
Ther Adv Respir Dis; 2020; 14():1753466620926853. PubMed ID: 32436445
[TBL] [Abstract][Full Text] [Related]
18. The Antiviral, Anti-Inflammatory Effects of Natural Medicinal Herbs and Mushrooms and SARS-CoV-2 Infection.
Shahzad F; Anderson D; Najafzadeh M
Nutrients; 2020 Aug; 12(9):. PubMed ID: 32854262
[TBL] [Abstract][Full Text] [Related]
19. Treatments for COVID-19: emerging drugs against the coronavirus.
Potì F; Pozzoli C; Adami M; Poli E; Costa LG
Acta Biomed; 2020 May; 91(2):118-136. PubMed ID: 32420936
[TBL] [Abstract][Full Text] [Related]
20. Current targeted therapeutics against COVID-19: Based on first-line experience in China.
Zhang Y; Xu Q; Sun Z; Zhou L
Pharmacol Res; 2020 Jul; 157():104854. PubMed ID: 32360585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
